Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04417062 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04417062 · ClinicalTrials.gov record · last posted 2026-08-20

Olaparib With Ceralasertib in Recurrent Osteosarcoma

StatusActive, Not Recruiting
PhasePhase 2
Started2020-11-24
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: * Olaparib * Ceralasertib

Protocol amendment history 3 changes detected by DataLookout

2026-08-21
Primary endpoint(s) modified
WasCohort 1 Event Free at 4 months, Cohort 2 paired pre-/post-treatment tumor Assessment
NowNumber of Participants Submitted Both Pre/Post-treatment Tumor Specimen (Cohort 2), Number of Participants Who Were Event-free at 4 Months (Cohort 1)
2026-08-21
Enrollment reduced: 63 → 49 participants
2026-08-21
Completion pushed: 2026-06-01 → 2026-12-01
Trial Details
NCT Number NCT04417062
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Osteosarcoma Institute, AstraZeneca
Conditions Osteosarcoma, Osteosarcoma Recurrent
Enrollment 49 participants
Start Date 2020-11-24
Primary Completion 2025-06-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-20